Galera Therapeutics (GRTX) Competitors $0.04 0.00 (-5.29%) As of 02/21/2025 02:07 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends GRTX vs. AYTU, CYCN, CELZ, AIM, DWTX, INDP, NLSP, CNSP, NEUP, and ADXNShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), Dogwood Therapeutics (DWTX), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), CNS Pharmaceuticals (CNSP), Neuphoria Therapeutics Inc. - Common Stock (NEUP), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Aytu BioPharma Cyclerion Therapeutics Creative Medical Technology AIM ImmunoTech Dogwood Therapeutics Indaptus Therapeutics NLS Pharmaceutics CNS Pharmaceuticals Neuphoria Therapeutics Inc. - Common Stock Addex Therapeutics Aytu BioPharma (NASDAQ:AYTU) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in AYTU or GRTX? 33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 2.8% of Aytu BioPharma shares are held by insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AYTU or GRTX? In the previous week, Aytu BioPharma's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score. Company Overall Sentiment Aytu BioPharma Neutral Galera Therapeutics Neutral Which has better valuation & earnings, AYTU or GRTX? Aytu BioPharma has higher revenue and earnings than Galera Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$81M0.10-$15.84M-$1.45-0.93Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.12 Does the MarketBeat Community prefer AYTU or GRTX? Aytu BioPharma received 205 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote. CompanyUnderperformOutperformAytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Galera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Is AYTU or GRTX more profitable? Galera Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. Galera Therapeutics' return on equity of 0.00% beat Aytu BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma-7.62% -19.30% -4.80% Galera Therapeutics N/A N/A -99.34% Which has more risk and volatility, AYTU or GRTX? Aytu BioPharma has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. SummaryGalera Therapeutics beats Aytu BioPharma on 7 of the 12 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.37M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.125.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book-0.026.717.644.62Net Income-$59.08M$138.55M$3.19B$245.94M7 Day PerformanceN/A-2.63%-2.11%-2.62%1 Month PerformanceN/A-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.04-5.3%N/A-77.4%$2.37MN/A-0.1230Gap UpAYTUAytu BioPharma1.0241 of 5 stars$1.39+0.4%N/A-55.0%$8.52M$81M-1.13160High Trading VolumeCYCNCyclerion Therapeutics0.7879 of 5 stars$3.12+3.0%N/A-1.1%$8.46M$1.62M0.0030CELZCreative Medical Technology0.8936 of 5 stars$4.74+3.3%N/A+28.0%$8.30M$10,000.00-1.255Gap DownHigh Trading VolumeAIMAIM ImmunoTech1.7411 of 5 stars$0.13-6.9%$2.75+2,031.8%-67.1%$8.23M$200,000.00-0.2720High Trading VolumeDWTXDogwood TherapeuticsN/A$6.13-8.6%N/AN/A$8.15MN/A-0.945INDPIndaptus Therapeutics3.1036 of 5 stars$0.80+2.1%$8.50+963.8%-52.9%$8.15MN/A-0.476Gap UpNLSPNLS PharmaceuticsN/A$2.26-1.7%N/A+364.1%$8.14MN/A0.006Gap UpCNSPCNS Pharmaceuticals2.2769 of 5 stars$0.14+29.9%$0.50+257.1%-99.5%$8.05MN/A0.005Stock SplitNews CoverageGap UpHigh Trading VolumeNEUPNeuphoria Therapeutics Inc. - Common Stock1.2883 of 5 stars$4.94+7.4%$21.00+325.1%N/A$8.05M$10,000.000.00N/AEarnings ReportADXNAddex Therapeutics2.5244 of 5 stars$7.50+6.2%$30.00+300.3%-25.0%$7.95M$1.83M-22.0430 Related Companies and Tools Related Companies AYTU Competitors CYCN Competitors CELZ Competitors AIM Competitors DWTX Competitors INDP Competitors NLSP Competitors CNSP Competitors NEUP Competitors ADXN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
